Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes | RxWiki

Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes

Overview[ - collapse ][ - ]

Purpose	It has been shown in previous study that progressive glycemic deterioration was associated with progressive loss of b-cell function, measured by the decrease in plasma insulin levels, irrespective of the therapy used (diet, sulfonylureas or metformin).There is growing evidence that thiazolidinediones could have a positive action on the b-cell function. But it has not yet been demonstrated that they could protect from a deterioration in insulin secretion in the long term. So, it appears interesting to study the long term evolution of the b-cell function and the possible protection with rosiglitazone in patients with type 2 diabetes showing evidence of loss of b-cell function with metformin alone.
Condition	Type 2 Diabetes Mellitus
Intervention	Drug: rosiglitazone-metformin Drug: Metformin Drug: metformin+ gliclazide
Phase	Phase 4
Sponsor	GlaxoSmithKline
Responsible Party	GlaxoSmithKline
ClinicalTrials.gov Identifier	NCT00367055
First Received	August 21, 2006
Last Updated	July 20, 2010
Last verified	July 2010

Tracking Information[ + expand ][ + ]

First Received Date	August 21, 2006
Last Updated Date	July 20, 2010
Start Date	October 2004
Estimated Primary Completion Date	October 2008
Current Primary Outcome Measures	Median Change From Baseline in the Insulin Secretory Capacity After a 36-month Treatment [Time Frame: Baseline and Month 36] [Designated as safety issue: No]Change from baseline in the insulin secretory capacity was measured by the assesment of blood insulin concentrations (conc.) using the hyperglycaemic clamp (HC) technique, per intravenous glucose perfusion by a catheter. Change from baseline for insulin conc peaks (highest conc level) was calculated as the Month 36 value minus the baseline value. Insulin secretion was assessed by calculating AUC during the first 10 minutes of HC (incremental and total AUC0-10 min) and the AUC after the first 10 minutes of the HC (10-180min).
Current Secondary Outcome Measures	Median Change From Baseline in the Ratio M/I After a 36-month Treatment [Time Frame: Baseline and Month 36] [Designated as safety issue: No] Median Change From Baseline in the Insulin Secretion Capacity After an 18-month Treatment [Time Frame: Baseline and Month 18] [Designated as safety issue: No]Change from baseline was calculated as the Month 18 value minus the baseline value. Insulin secretion capacity is measured in blood (blood level of insulin) and is a response of the pancreatic beta-cells to hyperglycemia induced by a glucose IV bolus, then infusion. Hyperglycemic clamp (HC) is a reference technique to evaluate the initial and the secondary phases of insulin secretion. Mean Change From Baseline in HbA1c at Month 36 [Time Frame: Baseline and Month 36] [Designated as safety issue: No]Change from baseline was calculated as the Month 36 value minus the baseline value. HbA1c levels were measured by blood draw. Mean Change From Baseline in FBG at Month 36 [Time Frame: Baseline and Month 36] [Designated as safety issue: No]Change from baseline was calculated as the Month 36 value minus the baseline value. FBG levels were measured by blood draw. Median Change From Baseline in Insulin Resistance Index (HOMA-IR) After a 36-month Treatment [Time Frame: Baseline and Month 36] [Designated as safety issue: No] Median Change From Baseline in Beta Cell Function Index (HOMA-beta) After a 36-month Treatment [Time Frame: Baseline and Month 36] [Designated as safety issue: No] Mean Change From Baseline in CPP Total and Incremental AUC T0-T30 After a 36-month Treatment [Time Frame: Baseline and Month 36] [Designated as safety issue: No] Mean Change From Baseline in CPP Concentration Peak and Incremental Concentration Peak T0-T30 After a 36-month Treatment [Time Frame: Baseline and Month 36] [Designated as safety issue: No] Mean Change From Baseline in Insulin Sensitivity Index at Months 18 and 36 [Time Frame: Baseline and Months 18 and 36] [Designated as safety issue: No]Change from baseline was calculated as the Month 18 and 36 values minus the baseline value. Insulin sensitivity is measured as the quantity of glucose metabolized per unit of plasma insulin concentration.

Descriptive Information[ + expand ][ + ]

Brief Title	Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes
Official Title	Comparison of the Action of the Rosiglitazone-metformin Fixed-dose Combination and of a Metformin-sulfonylurea Free Combination on the B-cell Function in Type 2 Diabetic Patients Not Controlled With Metformin Alone.
Brief Summary	It has been shown in previous study that progressive glycemic deterioration was associated with progressive loss of b-cell function, measured by the decrease in plasma insulin levels, irrespective of the therapy used (diet, sulfonylureas or metformin).There is growing evidence that thiazolidinediones could have a positive action on the b-cell function. But it has not yet been demonstrated that they could protect from a deterioration in insulin secretion in the long term. So, it appears interesting to study the long term evolution of the b-cell function and the possible protection with rosiglitazone in patients with type 2 diabetes showing evidence of loss of b-cell function with metformin alone.
Detailed Description	Not Provided
Study Type	Interventional
Study Phase	Phase 4
Study Design	Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Condition	Type 2 Diabetes Mellitus
Intervention	Drug: rosiglitazone-metformin Drug: Metformin Drug: metformin+ gliclazide Other Names: rosiglitazone-metformin Metformin metformin+ gliclazide
Study Arm (s)	Not Provided

Recruitment Information[ + expand ][ + ]

Recruitment Status	Completed
Estimated Enrollment	84
Estimated Completion Date	October 2008
Estimated Primary Completion Date	October 2008
Eligibility Criteria	INCLUSION CRITERIA: - Males and females 40 to 75 years of age (inclusive at the time of screening) - Type 2 diabetes mellitus as defined by the WHO criteria, diagnosed for at least 1 year - Subjects receiving 1.5 to 3g of metformin alone at a constant dose for at least 8 weeks prior to visit 1 - Patients with 6.5% < HbA1c > 8% at visit 1 and visit 2 - 25 < BMI < 35 EXCLUSION CRITERIA: - Patient with type 1 diabetes - Treatment with other hypoglycaemic agents than metformin in the last 3 months - FPG >200 mg/dL at visit 2 - Hypersensitivity to the studied treatments (rosiglitazone, metformin chlorhydrate, gliclazide) - Congestive heart failure (NYHA class I to IV), unstable or severe angina, recent myocardial infarction - Respiratory insufficiency - Subjects who have required the use of insulin for glycaemic control in the past 6 months prior to visit 1 (except during pregnancy or acute episodes such as hospitalization, trauma or infection) or subjects with a history of metabolic acidosis including diabetic ketoacidosis - Anemia defined by haemoglobin concentration <11.0 g/dL for males and <10.0 g/dL for females - Renal disease or renal dysfunction, e.g. as suggested by serum creatinine levels ≥135.0 µmol/L in males and ≥110.0 µmol/L in females and/or creatinine clearance <40 mL/min - Presence of clinically significant hepatic disease, with ALT, AST, total bilirubin, alkaline phosphatase >2.5 times the upper limit of the normal reference range - Subjects with chronic diseases requiring periodic ot intermittent treatment with oral or IV corticosteroids - Subjects receiving danazol, miconazole or phenylbutazone - Active alcohol, drug or medication abuse within the last 6 months or any condition that would indicate the likelihood of poor subject compliance - Women who are lactating, pregnant or planning to become pregnant - Any clinically significant abnormality identified at screening which, in the investigator's judgement, makes the subject unsuitable for inclusion in the study - Use of any other investigational agent within 30 days or 5 half-lives (whichever is longer) prior to visit 1 - Subjects who receive or anticipate receiving radiocontrast dye during the study
Gender	Both
Ages	40 Years
Accepts Healthy Volunteers	No
Contacts	Not Provided
Location Countries	Not Provided

Administrative Information[ + expand ][ + ]

NCT Number	NCT00367055
Other Study ID Numbers	101765
Has Data Monitoring Committee	Not Provided
Information Provided By	GlaxoSmithKline
Study Sponsor	GlaxoSmithKline
Collaborators	Not Provided
Investigators	Study Director: GSK Clinical Trials, MD GlaxoSmithKline
Verification Date	July 2010